Criteria, Challenges, and Opportunities for Acellularized Allogeneic/Xenogeneic Bone Grafts in Bone Repairing.
Majid SharifiRasoul KheradmandiMajid SalehiMorteza AlizadehTimo L M Ten HagenMojtaba FalahatiPublished in: ACS biomaterials science & engineering (2022)
As bone grafts become more commonly needed by patients and as donors become scarcer, acellularized bone grafts (ABGs) are becoming more popular for restorative purposes. While autogeneic grafts are reliable as a gold standard, allogeneic and xenogeneic ABGs have been shown to be of particular interest due to the limited availability of autogeneic resources and reduced patient well-being in long-term surgeries. Because of the complete similarity of their structures with native bone, excellent mechanical properties, high biocompatibility, and similarities of biological behaviors (osteoinductive and osteoconductive) with local bones, successful outcomes of allogeneic and xenogeneic ABGs in both in vitro and in vivo research have raised hopes of repairing patients' bone injuries in clinical applications. However, clinical trials have been delayed due to a lack of standardized protocols pertaining to acellularization, cell seeding, maintenance, and diversity of ABG evaluation criteria. This study sought to uncover these factors by exploring the bone structures, ossification properties of ABGs, sources, benefits, and challenges of acellularization approaches (physical, chemical, and enzymatic), cell loading, and type of cells used and effects of each of the above items on the regenerative technologies. To gain a perspective on the repair and commercialization of products before implementing new research activities, this study describes the differences between ABGs created by various techniques and methods applied to them. With a comprehensive understanding of ABG behavior, future research focused on treating bone defects could provide a better way to combine the treatment approaches needed to treat bone defects.
Keyphrases
- bone mineral density
- soft tissue
- bone loss
- clinical trial
- stem cell transplantation
- bone marrow
- end stage renal disease
- stem cells
- type diabetes
- ejection fraction
- postmenopausal women
- cell proliferation
- mesenchymal stem cells
- cell therapy
- mental health
- chronic kidney disease
- single cell
- oxidative stress
- low dose
- case report
- patient reported outcomes
- metabolic syndrome
- mass spectrometry
- current status
- hematopoietic stem cell
- quality improvement